Dr. Agarwal's Health Care Limited
₹508.35+₹19.65 (+4.0%)
Last close · Data as of Oct 30, 2026
- Market cap
- ₹15,850 Cr
- P/E
- 302.0x
- EV / EBITDA
- 62.8x
- Revenue
- ₹1,044 Cr
- Net margin
- 2.9%
- ROCE
- 11.9%
Price chart
Technical chartScreen technicals →-2.1% over the last year
Daily closes.
Go deeper
Technical chart: candles, 9 moving averages, RSI, MACD and drawing tools
Performance
Price change over each period, before dividends.
- 1M
- +5.9%
- 3M
- +5.6%
- 6M
- +14.4%
- 1Y
- -2.1%
- 5Y
- +26.4%
52-week range
Day change +₹19.65 (+4.0%) from ₹489 to ₹508 · Last close Oct 30, 2026
Best weekday to invest, historically
The same weekly amount in AGARWALEYE, bought on each weekday since 2025.
AI Summary
Indian StockStrengths1
- Strong 5-year revenue CAGR of 27.5%
Concerns1
- Low return on equity of 2.0%
Rule-based from financial data. Not advice.
About the company
Dr. Agarwal's Health Care Limited operates eye hospitals in India and internationally. It offers cataract surgeries, such as small incision cataract surgery, phacoemulsification, robotic cataract surgery, and glued intraocular lens treatments; and refractive surgeries, including surgical procedures to correct the refractive error of the eye to get rid of or reduce dependence on glasses and contact lens.
Read moreShow less
Dr. Agarwal's Health Care Limited operates eye hospitals in India and internationally. It offers cataract surgeries, such as small incision cataract surgery, phacoemulsification, robotic cataract surgery, and glued intraocular lens treatments; and refractive surgeries, including surgical procedures to correct the refractive error of the eye to get rid of or reduce dependence on glasses and contact lens. The company also provides surgical retinal treatments, corneal transplantation and pinhole pupilloplasty, oculoplasty, and surgeries for the treatment of glaucoma and pterygium; doctor consultation services; and diagnostic services for eye disorders along with non-surgical treatments, including retinal laser therapy and dry eye treatment services. It also sells glasses, lenses, contact lenses, and frames; and eye care-related pharmaceutical products. The company was incorporated in 2010 and is based in Chennai, India.
- Sector
- Healthcare
- Shares outstanding
- 31.7 Cr shares
- ISIN
- INE943P01029
- BSE code
- 544350
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- ₹15,850 Cr
- P/E
- 302.0x
- P/B
- 8.1x
- EV / EBITDA
- 62.8x
- EV / Sales
- 19.7x
- P/S
- 19.0x
- Earnings yield
- 0.3%
- 52-week high
- ₹562.05
- 52-week low
- ₹406.15
Profitability
- Operating margin
- 26.8%
- Net margin
- 2.9%
- EBITDA margin
- 31.4%
- ROE
- 2.0%
- ROCE
- 11.9%
- ROA
- 1.1%
- Dividend payout
- 0.0%
- Tax rate
- 47.0%
- Other income, % of PBT
- 84.4%
Growth
- RevenueLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹1,044 Cr
- Revenue growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 25.0%
- Revenue CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 27.5%
- EBITDALatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹262 Cr
- EBITDA growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 74.7%
- Net profit growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -8.3%
- Cash from operationsLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹222 Cr
- CFO growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 45.1%
- Free cash flowLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹5.00 Cr
- Asset growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 57.6%
Solvency and efficiency
- Current ratio
- 2.94
- Debt / Equity
- 0.54
- Debt / Assets
- 0.30
- Debt / EBITDA
- 2.52
- Interest coverage
- 2.55
- Financial leverage
- 1.78
- CFO / Net profit
- 9.25
- Cash / Market cap
- 1.6%
- Cash per share
- ₹7.82
- Asset turnover
- 0.38
- Fixed asset turnover
- 0.64
- Capital intensity
- 1.56
- Debtor days
- 22 days
- Inventory turnover
- 2.70
- Cash conversion cycle
- -226 days
Where the revenue went
Of every ₹100 of FY2025 revenue, ₹2 was left as net profit.
| From | To | Amount |
|---|---|---|
| Sales | Expenses | ₹795 Cr |
| Sales | Operating profit | ₹249 Cr |
| Operating profit | Interest | ₹94 Cr |
| Operating profit | Depreciation | ₹155 Cr |
| Other income | Depreciation | ₹1 Cr |
| Other income | Profit before tax | ₹39 Cr |
| Profit before tax | Tax and other | ₹17 Cr |
| Profit before tax | Net profit | ₹22 Cr |
Revenue and net profit
Revenue grew 25.0% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2021 | ₹232 Cr | -₹54 Cr |
| FY2022 | ₹362 Cr | -₹1 Cr |
| FY2023 | ₹598 Cr | ₹32 Cr |
| FY2024 | ₹835 Cr | ₹24 Cr |
| FY2025 | ₹1,044 Cr | ₹22 Cr |
Cash flows
FY2025: ₹208 Cr from operations, -₹369 Cr free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2021 | ₹46 Cr | ₹20 Cr |
| FY2022 | ₹78 Cr | -₹20 Cr |
| FY2023 | ₹153 Cr | -₹283 Cr |
| FY2024 | ₹222 Cr | -₹596 Cr |
| FY2025 | ₹208 Cr | -₹369 Cr |
Growth
Latest fiscal year FY2025 (ending March): each figure with its change over the year before.
- Revenue
- ₹1,044 Cr+25.0%1Y
- Net profit
- ₹22 Cr-8.3%1Y
- Cash from operations
- ₹208 Cr
- Free cash flow
- -₹369 Cr
- Revenue CAGR, 5Y
- 27.5%
- EBITDA CAGR, 5Y
- 36.6%
| Year | Revenue | Operating income | EBITDA | Net profit | CFO | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹1,044 Cr | ₹249 Cr | — | ₹22 Cr | ₹208 Cr | -₹369 Cr | 1.1% | +25.0% | -8.3% |
Monthly returns
Month-by-month returns of AGARWALEYE across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Liabilities and equity | ₹2,837 Cr |
| Equity capital | ₹32 Cr |
| Reserves | ₹1,902 Cr |
| Borrowings | ₹568 Cr |
| Other liabilities | ₹335 Cr |
| Assets | ₹2,837 Cr |
| Fixed assets | ₹1,591 Cr |
| Capital work in progress | ₹18 Cr |
| Investments | ₹729 Cr |
| Other assets | ₹498 Cr |
Market cap against peers
8 peers: same sector group, nearest by size.
P/E against peers
AGARWALEYE trades at 302.0x earnings against a peer median of 52.6x (a 474% premium).
Not shown (no positive earnings and no EV / Sales): JUBILANT PHARMOVA LIMITED.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Dr. Agarwal's Health Care LimitedAGARWALEYEthis companyP/E ↑ premium | ₹15,850 Cr | 302.0x | 8.1x | 2.0% | 62.8x |
| Ventive Hospitality LimitedVENTIVE | ₹17,846 Cr | 91.9x | 3.9x | 49.7% | 60.7x |
| Poly Medicure LtdPOLYMED | ₹17,352 Cr | 49.8x | 6.0x | 17.3% | 42.5x |
| Cohance Lifesciences LimitedCOHANCE | ₹17,161 Cr | 46.3x | 3.9x | 14.6% | 37.0x |
| JUBILANT PHARMOVA LIMITEDJUBLPHARMA | ₹16,581 Cr | — | 7.4x | 1.3% | 140.4x |
| ALEMBIC PHARMACEUTICALS LIMITEDAPLLTD | ₹15,765 Cr | 35.5x | 3.0x | 13.6% | 15.2x |
| Natco Pharma Ltd.NATCOPHARM | ₹15,582 Cr | 10.3x | 1.9x | 23.4% | 8.8x |
| Granules India Ltd.GRANULES | ₹14,372 Cr | 39.7x | 4.0x | 14.0% | 18.5x |
| ACUTAAS CHEMICALS LIMITEDACUTAAS | ₹13,806 Cr | 61.2x | 9.7x | 6.5% | 154.5x |
| Peer median | — | 52.6x | 5.9x | 12.1% | 38.3x |
Year-to-date ROI
AGARWALEYE since 1 January, against earlier years.
Historical volatility
AGARWALEYE's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, in ₹ crore, grouped into plain-language lines.
Figures in ₹ crore as reported, fiscal years ending March, newest first; the trailing twelve months (TTM) last.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2021 | 14.0% |
| FY2022 | 24.0% |
| FY2023 | 27.0% |
| FY2024 | 27.0% |
| FY2025 | 24.0% |
| Line | FY2025 |
|---|---|
| RevenueSales | ₹1,044 Cr |
| Costs | |
| Interest | ₹94 Cr |
| Expenses | ₹795 Cr |
| Operating profitOperating Profit | ₹249 Cr |
| Other income and charges | |
| Profit before tax | ₹39 Cr |
| Tax | |
| Net profitNet Profit | ₹22 Cr |
| Per share |
| Line | FY2025 |
|---|---|
| Liabilities and equityTotal Liabilities | ₹2,837 Cr |
| Equity capitalEquity Capital | ₹32 Cr |
| Reserves | ₹1,902 Cr |
| Borrowings | ₹568 Cr |
| Other liabilitiesOther Liabilities | ₹335 Cr |
| AssetsTotal Assets | ₹2,837 Cr |
| Fixed assetsFixed Assets | ₹1,591 Cr |
| Capital work in progressCWIP | ₹18 Cr |
| Investments | ₹729 Cr |
| Other assetsOther Assets | ₹498 Cr |
| Line | FY2025 |
|---|---|
| Operating cash flowCash from Operating Activity | ₹208 Cr |
| Investing cash flowCash from Investing Activity | -₹577 Cr |
| Financing cash flowCash from Financing Activity | ₹374 Cr |
| Change in cashNet Cash Flow | ₹5 Cr |
Learn while you research
Academy chapters picked for Dr. Agarwal's Health Care Limited and the metrics on this page.
- 01 Taxes on Investments (India)LTCG, STCG, dividend tax, what every Indian investor needs.6 min read
- 02 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 03 Valuation Multiples ExplainedThis stock trades at a P/E of 302.0, learn when high multiples are justified.6 min read
- 04 Growth Investing25% revenue growth is in the top tier, learn how to value growth.7 min read
- 05 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 06 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read